Changing the course of blood cancers

Latest updates


Geron announces positive top-line results from the IMerge Phase 3 clinical trial evaluating imetelstat, the Company’s first-in-class telomerase inhibitor, in lower risk MDS

The trial met its primary efficacy endpoint of 8-week TI and a key secondary endpoint of 24-week TI, demonstrating highly statistically significant and clinically meaningful benefit of imetelstat versus placebo with safety results consistent with prior imetelstat clinical trials and no new safety signals.


Recent presentations at the American Society of Hematology (ASH) 2022 Annual Meeting reflect the differentiating qualities and broad potential of imetelstat in hematologic malignancies

ASH

We made the most of our time at ASH22 in New Orleans! It was great meeting new people, seeing some familiar faces and connecting with some of the best minds in hematology!


Publications

Longer follow-up data from the Phase 2 study in lower risk myelodysplastic syndromes (MDS)

Imetelstat Achieved Prolonged, Continuous Transfusion Independence in Patients With Heavily Transfused Non-Del(5q) Lower Risk MDS (LR-MDS) Relapsed/Refractory to Erythropoiesis Stimulating Agents Within the IMerge Phase 2 Study

Platzbecker, et al.


Phase 2 results from the IMerge trial in lower risk myelodysplastic syndromes (MDS)

Imetelstat Achieves Meaningful and Durable Transfusion Independence in High Transfusion-Burden Patients With Lower-Risk Myelodysplastic Syndromes in a Phase II Study


Phase 2 results from the IMbark trial in relapsed/refractory myelofibrosis (MF)

Randomized, Single-Blind, Multicenter Phase II Study of Two Doses of Imetelstat in Relapsed or Refractory Myelofibrosis

Mascarenhas, et al.